Old Web
English
Sign In
Acemap
>
authorDetail
>
Wayne P. Rothbaum
Wayne P. Rothbaum
relapsed refractory
Internal medicine
Myelofibrosis
Medicine
Oncology
4
Papers
5
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A Phase 1b/2 Study of Navtemadlin (KRT-232), a Murine Double Minute 2 Inhibitor, Combined with a BCR-ABL Tyrosine Kinase Inhibitor in Patients with Relapsed/Refractory, TP53 WT , Ph+ Chronic Myeloid Leukemia
2021
Blood
Jorge E. Cortes
Omer Jamy
Guillermo Ortí
Felipe Prosper
Sebastian Grosicki
Anne Uyei
Wayne P. Rothbaum
Franck E. Nicolini
Show All
Source
Cite
Save
Citations (1)
BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).
2021
Journal of Clinical Oncology
Srdan Verstovsek
Haifa Kathrin Al-Ali
John Mascarenhas
Adam J. Mead
Andrew C. Perkins
Alessandro M. Vannucchi
Anne Uyei
Wayne P. Rothbaum
Jesse McGreivy
Jean-Jacques Kiladjian
Show All
Source
Cite
Save
Citations (1)
Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)
2021
Blood
Pankit Vachani
Andrzej Lange
Regina García-Delgado
Haifa Kathrin Al-Ali
Jesús-María Hernández-Rivas
Jean-Jacques Kiladjian
Alessandro M. Vannucchi
Andrew C. Perkins
Venu Valmeekam
Cecile M. Krejsa
Anne Uyei
Jesse McGreivy
Wayne P. Rothbaum
John Mascarenhas
Srdan Verstovsek
Show All
Source
Cite
Save
Citations (0)
Libya and the Aerial Incident at Lockerbie: What Lessons for International Extradition Law?
1993
Michigan journal of international law
Christopher C. Joyner
Wayne P. Rothbaum
Show All
Source
Cite
Save
Citations (3)
1